Foghorn Therapeutics CEO Adrian Gottschalk shares an update on the company’s FHD-286 combination study in AML and what’s ahead for Foghorn’s pipeline. More from Flagship @ JPM2024 here.
Related Companies
- Foghorn Therapeutics Founded: 2016
More from:
Human Health
Three Questions with Junaid Bajwa, Flagship Senior Partner, Head of UK, and Science Partner for Pioneering Intelligence
The Future of Genetic Medicines is Here
Three Questions with Hari Pujar, Founding President of Mirai Bio and Flagship Operating Partner
The Next Generation of Biologics Are Supranatural
Pioneering Profile
Q&A with Molly Gibson on Leading Company Origination
Letter of Support
